In July 2024, Rapid Micro Biosystems Completed An Enterprise-wide Review To Realize Operational Efficiencies, The Company Will Reduce Its Current Workforce, Close Open And Planned Positions, And Reduce Other Non-headcount-related Expenses Across The...
In July 2024, Rapid Micro Biosystems Completed An Enterprise-wide Review To Realize Operational Efficiencies, The Company Will Reduce Its Current Workforce, Close Open And Planned Positions, And Reduce Other Non-headcount-related Expenses Across The...
2024年7月，Rapid Micro Biosystems進行了一項企業-wide審查，以實現運營效率，公司將減少其當前工作人員，關閉已開放和計劃職位，並在公司整個業務上減少其他非人員開銷。
In July 2024, Rapid Micro Biosystems Completed An Enterprise-wide Review To Realize Operational Efficiencies, The Company Will Reduce Its Current Workforce, Close Open And Planned Positions, And Reduce Other Non-headcount-related Expenses Across The Business
2024年7月，快速微生物生產系統公司進行了全企業審查以實現運營效率，公司將在業務各個領域減少現有員工，關閉已開放和計劃職位，以及裁減其他與人員數無關的費用。
These actions are expected to result in approximately $7 million in annual cash savings and enable the Company to achieve positive cash flow by the end of 2027 without additional financing.
這些行動預計將產生約700萬美元的年度現金儲蓄，並使公司在2027年底之前實現正現金流，無需額外融資。
The Company does not expect these actions to impact its 2024 revenue or gross margin outlook and plans to continue to invest in key initiatives that are expected to drive future revenue growth and gross margin improvement, including product development and cost reduction programs.
公司預計這些行動不會影響其2024年營業收入或毛利率預期，並計劃繼續投資於預計推動未來營收增長和毛利率改善的關鍵舉措，包括產品開發和成本削減計劃。
The Company expects to record a related charge of approximately $0.7 million in the third quarter of 2024.
公司預計將在2024年第三季度錄得相關費用約70萬美元。
資訊熱榜
更新時間